"The story does not mention costs, but it is understandable that pricing may not be available with a drug so early in development. The story does a good job of quantifying the benefits of treatment in absolute terms by providing the actual number of months with no new lesions for both the new drug group and the standard treatment group. The story mentions that potential harms of the drug include a drop in white blood cells, back pain and fatigue. The story adequately describes the design of the current study. The story accurately describes the study as ""small"" and ""preliminary."" The story does not overstate the seriousness or prevalence of melanoma. The story quotes one independent expert in addition to a representative of the company. The story does mention that ""there are very few drugs available for people with advanced melanoma."" However, the story could have elaborated on the available alternatives and how this new drug may fit in with the existing options. The story clearly states that the drug is in very early stages of development and has not yet been submitted for approval. The story clearly states that the drug is new. There is no way to know if the story relied on a press release as the sole source of information."
Skin cancer drug said to show promise